IS Pharma acquires cancer pain treatment from Camarus
This article was originally published in Scrip
Executive Summary
IS Pharma has paid €1.75 million for exclusive rights to Camarus of Sweden's oncology supportive care product Episil, under a licence and distribution agreement in all European markets except Scandinavia.